News

In October, we added 134 citations in DIDB, including 51 in vitro (with 29 articles published in October 2022) and 83 in vivo articles (with 40 articles published in October 2022).

Five recently approved NDAs and BLAs were also added: daxibotulinumtoxina (DAXXIFY), deucravacitinib (SOTYKTU), eflapegrastim (ROLVEDON), omidenepag isopropyl (OMLONTI), and terlipressin (TERLIVAZ).

You can check the citations that are recently published and entered in DIDB and all the NDAs/BLAs in DIDB.

As always, feel free to contact us if you have any questions or comments.

In September, we added 137 citations in DIDB, including 70 in vitro (with 36 articles published in September 2022) and 67 in vivo articles (with 40 articles published in September 2022).

Two recently approved BLAs were also added: olipudase alfa (XENPOZYME), spesolimab (SPEVIGO).

You can check the citations that are recently published and entered in DIDB and all the NDAs/BLAs in DIDB.

As always, feel free to contact us if you have any questions or comments.

The DDI Marker Studies Knowledgebase (replacing the previous combined and individual lists of CYP/P-gp substrates and perpetrators) has been updated in October 2022, and is available in the DIDB Resource Center.

We continue to expand the Knowledgebase by adding more transporter data. In this update, 42 compounds (including 13 endogenous biomarkers) were added as OATP1B/1B3 substrates based on clinical DDI data and/or pharmacogenetic findings. In addition, 16 compounds were identified as substates/inhibitors/inducers of CYP enzymes and transporters (P-gp and BCRP). Among them, 20% could lead to strong drug interactions.

In addition to substrates, inhibitors and inducers of CYPs and transporters, the Knowledgebase provides useful information on the compounds therapeutic class, clinical recommended dosage, pharmacokinetics (e.g. dose proportionality accumulation ratio, time to steady-state), QT prolongation, and NTI characteristics.

As always, feel free to contact us if you have any questions or comments.

In August, we added 104 citations in DIDB, including 39 in vitro (with 22 articles published in August 2022) and 65 in vivo articles (with 37 articles published in August 2022).

You can check the citations that are recently published and entered in DIDB and all the NDAs/BLAs in DIDB.

As always, feel free to contact us if you have any questions or comments.

In July, we added 73 citations in DIDB, including 35 in vitro (with 21 articles published in July 2022) and 38 in vivo articles (with 33 articles published in July 2022).

Two recently approved NDAs were also added: mavacamten (CAMZYOS), vutrisiran (AMVUTTRA).

Of note, all new drugs approved by the FDA from January to July this year (N = 16) have been curated in DIDB, and a DDI drug monograph for each drug was created.

You can check the citations that are recently published and entered in DIDB and all the NDAs/BLAs in DIDB.

As always, feel free to contact us if you have any questions or comments.

The DDI Marker Studies Knowledgebase (replacing the previous combined and individual lists of CYP/P-gp substrates and perpetrators) has been updated in July 2022, and is available in the DIDB Resource Center.

In addition to substrates, inhibitors and inducers of CYPs and transporters, the Knowledgebase provides useful information on the compounds therapeutic class, clinical recommended dosage, pharmacokinetics (e.g. dose proportionality accumulation ratio, time to steady-state), QT prolongation, and NTI characteristics.

As always, feel free to contact us if you have any questions or comments.